Skip to main content
SpringerLink
Log in

Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The mechanism of action of NSC 368390 (DUP-785, 6-fluoro-2-(2′-fluoro-1, 1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt) was studied using three different approaches. First, we studied growth inhibition by DUP-785 in L1210 leukemia cells and M5 melanoma cells. The concentrations causing 50% growth inhibition after 48 hr of culture were 5.8 and 0.6 μM, respectively. DUP-785 had to be present continuously throughout culture. Growth inhibition by 25 μM DUP-785 could be prevented by addition of 1 mM uridine or orotic acid to cultures of these cell lines; in M5 cells cytidine was also able to prevent growth inhibition. Dihydro-orotic acid (DHO) and carbamyl-aspartate were not able to prevent growth inhibition by DUP-785. Second, we studied accumulation of orotic acid and of orotidine induced by incubation with 1 μM pyrazofurin, an inhibitor of the orotate phosphoribosyl-transferase-orotidine-monophosphate decarboxylase complex. Addition of DUP-785 to the culture medium prevented the orotic acid accumulation. Furthermore, DUP-785 prevented accumulation of H14CO3 − into orotic acid of pyrazofurin-treated L1210 cells. Third, we measured the effect of DUP-785 on DHO-dehydrogenase (DHO-DH), since the results indicated that this enzyme was affected by DUP-785. DHO-DH was assayed in isolated rat liver mitochondria. The Km for L-DHO was about 12 μM. DUP-785 appeared to be a potent inhibitor of DHO-DH with an apparent Ki of about 0.1 μM and an apparent Ki′ of about 0.8 μM. The mode of inhibition appeared to be linear mixed type. After exposure of L1210 cells to 25 μM DUP-785 for 2 hr DHO-DH was almost completely inhibited. After suspension in fresh medium without drug, DHO-DH activity was recovered to about 60% after 24 hr. In conclusion, DUP-785 is a potent inhibitor of pyrimidine de novo biosynthesis, by inhibition of the mitochondrial enzyme DHO-DH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DHO-DH:

dihydroorotic acid dehydrogenase

DHO:

dihydroorotic acid

CA:

carbamyl-L-aspartate

IC50 :

concentration that causes 50% growth inhibition

PALA:

N-phosphonacetyl-L-aspartate

OPRT:

orotate-phosphoribosyltransferase

ODC:

orotidylate decarboxylase

HPLC:

high performance liquid chromatography

References

  1. Dexter DL, Hesson DP, Ardecky RJ, Rao GV, Tippett DL, Dusak BA, Paull KD, Plowman J, DeLarco BM, Narayanan VL, Forbes M: Activity of a novel 4-quinolinecarboxylic Acid, NSC 368390 [6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt], against experimental tumors. Cancer Res 45:5563–5568, 1985

    Google Scholar 

  2. Pinedo HM, Swartsmann G, Van Loenhout JWA, Hochster H, Ten Bokkel Huinink WW, Van der Vijgh WJF, Klein I, Dodion P, Winograd B, Vermorken JB: Phase I study of DUP-785 (NSC 368390) in solid tumors. (Abstr) Proc 5th NCI/EORTC Symp, Amsterdam, The Netherlands, 1986

  3. Chen SF, Ruben RL, Dexter DL: Effects of a novel antitumor agent, DUP-785 (6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt) on de novo pyrimidine biosynthesis. (Abstr) Proc Amer Assoc Cancer Res 27:298, 1986

    Google Scholar 

  4. Cadman EC, Dix DE, Handschumacher RE: Clinical, biological and biochemical effects of pyrazofurin. Cancer Res 38:682–688, 1978

    Google Scholar 

  5. Chen SF, Ruben RL, Dexter DL: Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 46:5014–5019, 1986

    Google Scholar 

  6. Peters GJ, Laurensse E, Sharma SL, Leyva A, Pinedo HM: Mechanism of action of DUP-785 — a new antimetabolite. Proc 5th NCI/EORTC Symp, Amsterdam, The Netherlands, (Abstr) 1986

  7. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM: Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′ deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46:20–28, 1986

    Google Scholar 

  8. Peters GJ, Laurensse E, Leyva A, Pinedo HM: A sensitive, non-radiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography. Anal Biochem 161:32–38, 1987

    Google Scholar 

  9. Peters GJ, Kraal I, Laurensse E, Leyva A, Pinedo HM: Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high performance liquid chromatography on a column with porous polymeric packing. J Chrom 307: 464–468, 1984

    Google Scholar 

  10. Peters GJ, Veerkamp JH: Pyrimidine metabolism in rat brain cortex and liver. Adv Exp Med Biol 165A:531–534, 1984

    Google Scholar 

  11. Cornish-Bowden A: A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143–144, 1974

    Google Scholar 

  12. Moyer JD, Handschumacher RE: Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Cancer Res 39: 3089–3094, 1979

    Google Scholar 

  13. Johnson RK: Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-aspartate in vivo. Biochem Pharmacol 26:81–84, 1977

    Google Scholar 

  14. Boytek P, Beisler JA, Abbasi MM, Wolpert-DeFilippes MK: Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine. Cancer Res 37:1956–1961, 1977

    Google Scholar 

  15. Tax WJM, Veerkamp JH, Trijbels FJM, Schretlen EDAM: Mechanism of allopurinol-mediated inhibition and stabilization of human orotate phosphoribosyltransferase and orotidine phosphate decarboxylase. Biochem Pharmacol 25:2025–2032, 1976

    Google Scholar 

  16. Tax WJM, Veerkamp JH, Schretlen EDAM: Pyrimidine metabolism in erythrocytes of the newborn. Biol Neonate 35:121–125, 1979

    Google Scholar 

  17. Bennett Jr LL, Smithers D, Rose LM, Adamson DJ, Thomas HJ: Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-l,4-naphthoquinone. Cancer Res 39:4868–4874, 1979

    Google Scholar 

  18. Kensler TW, Reck LJ, Cooney DA: Therapeutic effects of acivicin and N-(Phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(Phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma. Cancer Res 41:905–909, 1981

    Google Scholar 

  19. Chen JJ, Jones ME: The cellular location of dihydroorotate dehydrogenase: relation to de novo biosynthesis of pyrimidines. Arch Biochem Biophys 176:82–90, 1976

    Google Scholar 

  20. Jones ME: Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Ann Rev Biochem 49:253–279, 1980

    Google Scholar 

  21. Hines V, Keys III LD, Johnston M: Purification and properties of the bovine liver mitochondrial dihydroorotate dehydrogenase. J Biol Chem 24:11386–11392, 1986

    Google Scholar 

  22. Forman HJ, Kennedy J: Dihydroorotate-dependent superoxide production in rat brain and liver. A function of the primary dehydrogenase. Arch Biochem Biophys 173: 219–224, 1976

    Google Scholar 

  23. Santilli V, Skoda J, Gut J, Sorm F: Dihydro-5-azaorotic acid, the first specific inhibitor of dihydro-orotate dehydrogenase. Biochim Biophys Acta 155:623–625, 1968

    Google Scholar 

  24. Löffler M: On the role of dihydroorotate dehydrogenase in growth cessation of Ehrlich ascites tumor cells cultured under oxygen deficiency. Eur J Biochem 107:207–215, 1980

    Google Scholar 

  25. De Frees SA, Sawick DP, Cunningham BA, Morré DJ, Cassady JM, Heinstein PF: Design of dihydroorotate dehydrogenase inhibitors as potential tumor inhibitors. (Abstr) Proc Amer Assoc Cancer Res 19, 1984

  26. Smith SL, Douglas KT: Inhibition of ribonucleotide reductase by a flavone (quercetin) and a hydroxyquinone (lapachol). IRCS Med Sci 14:541–542, 1986

    Google Scholar 

  27. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res 43:3466–3492, 1983

    Google Scholar 

  28. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW: Improved therapeutic index with sequential N-Phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. Cancer Res 43:4653–4661, 1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Oncology, Free University Hospital, P.O. Box 7057, 1007, Amsterdam, MB, The Netherlands

    G. J. Peters, S. L. Sharma, E. Laurensse & H. M. Pinedo

Authors
  1. G. J. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. L. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Laurensse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. M. Pinedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peters, G.J., Sharma, S.L., Laurensse, E. et al. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). Invest New Drugs 5, 235–244 (1987). https://doi.org/10.1007/BF00175293

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175293

Key words

Search

Navigation